Novaphergan (Promethazine Hydrochloride)

Promethazine acts as a competitive antagonist at histamine H1 receptors, preventing histamine‑induced vasodilation and increased vascular permeability. Its additional anticholinergic and dopamine‑blocking activities contribute to its anti‑itch and anti‑emetic effects, making it effective for skin‑related allergic reactions.

The dosage of Novaphergan is determined by the prescribing clinician based on the severity of the skin condition, patient age, and response to therapy. Healthcare professionals select the appropriate amount and frequency of application according to individual therapeutic needs.

Safety data for promethazine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Pregnant or nursing individuals should discuss use with their healthcare provider.

To request Novaphergan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Novaphergan (promethazine) is a first‑generation H1 antagonist, which generally provides stronger sedation and anticholinergic effects compared with second‑generation antihistamines that are less sedating. Its broader receptor profile can be advantageous for severe itching but may increase the likelihood of side effects.

Novaphergan should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and extreme temperatures to maintain its stability and efficacy.

Novaphergan is applied topically to the affected skin area. The exact amount and frequency of application are prescribed by a healthcare professional, typically spreading a thin layer over the lesion and gently massaging it into the skin.

Serious risks include rare but severe allergic reactions such as anaphylaxis, blood disorders like agranulocytosis, seizures, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, rash, fever, or irregular heartbeat.

Novaphergan is contraindicated in individuals with known hypersensitivity to promethazine or any formulation components, patients with narrow‑angle glaucoma, and those taking MAO inhibitors. Caution is also advised for patients with severe hepatic impairment or a history of seizures.